2024. Skin Clearance, Treatment Response Off-therapy, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine. 8, 6 (Nov. 2024), s460. DOI:https://doi.org/10.25251/skin.8.supp.460.